Yale University, Department of Molecular, Cellular and Developmental Biology, USA.
Yale University, Department of Molecular, Cellular and Developmental Biology, USA; Department of Comparative Medicine, Yale University, USA; Department of Physiology, Yale University, USA; Yale Stem Cell Center, USA; Yale Program in Integrative Cell Signaling and Neurobiology of Metabolism, USA.
Mol Metab. 2021 Feb;44:101141. doi: 10.1016/j.molmet.2020.101141. Epub 2020 Dec 9.
Low testosterone in men (hypogonadism) is associated with obesity and type II diabetes. Testosterone replacement therapy has been shown to reverse these effects. However, the mechanisms by which testosterone regulates total fat mass, fat distribution, and metabolic health are unclear. In this study, we clarify the impact of hypogonadism on these parameters, as well as parse the role of testosterone from its downstream metabolites, dihydrotestosterone (DHT), and estradiol, in the regulation of depot-specific adipose tissue mass.
To achieve this objective, we utilized mouse models of male hypogonadism coupled with hormone replacement therapy, magnetic resonance imaging (MRI), glucose tolerance tests, flow cytometry, and immunohistochemical techniques.
We observed that castrated mice develop increased fat mass, reduced muscle mass, and impaired glucose metabolism compared with gonadally intact males. Interestingly, obesity is further accelerated in castrated mice fed a high-fat diet, suggesting hypogonadism increases susceptibility to obesogenesis when dietary consumption of fat is elevated. By performing hormone replacement therapy in castrated mice, we show that testosterone impedes visceral and subcutaneous fat mass expansion. Testosterone-derived estradiol selectively blocks visceral fat growth, and DHT selectively blocks the growth of subcutaneous fat. These effects are mediated by depot-specific alterations in adipocyte size. We also show that high-fat diet-induced adipogenesis is elevated in castrated mice and that this can be rescued by androgen treatment. Obesogenic adipogenesis is also elevated in mice where androgen receptor activity is inhibited.
These data indicate that hypogonadism impairs glucose metabolism and increases obesogenic fat mass expansion through adipocyte hypertrophy and adipogenesis. In addition, our findings highlight distinct roles for testosterone, DHT, and estradiol in the regulation of total fat mass and fat distribution and reveal that androgen signaling blocks obesogenic adipogenesis in vivo.
男性(性腺功能减退症)中的低睾酮与肥胖和 2 型糖尿病有关。已经证明睾酮替代疗法可以逆转这些影响。然而,睾酮调节总脂肪量、脂肪分布和代谢健康的机制尚不清楚。在这项研究中,我们阐明了性腺功能减退症对这些参数的影响,并解析了睾酮及其下游代谢物二氢睾酮(DHT)和雌二醇在调节特定脂肪组织质量中的作用。
为了实现这一目标,我们利用雄性性腺功能减退症的小鼠模型,结合激素替代疗法、磁共振成像(MRI)、葡萄糖耐量试验、流式细胞术和免疫组织化学技术。
我们观察到去势小鼠与性腺完整的雄性相比,脂肪量增加,肌肉量减少,葡萄糖代谢受损。有趣的是,高脂饮食喂养的去势小鼠肥胖进一步加速,表明当饮食中脂肪摄入增加时,性腺功能减退症会增加肥胖发生的易感性。通过对去势小鼠进行激素替代疗法,我们表明睾酮阻碍内脏和皮下脂肪量的扩张。睾酮衍生的雌二醇选择性地阻止内脏脂肪的生长,而 DHT 选择性地阻止皮下脂肪的生长。这些作用是通过脂肪细胞大小的特定部位改变介导的。我们还表明,高脂饮食诱导的脂肪生成在去势小鼠中增加,而雄激素治疗可以挽救这种情况。雄激素受体活性被抑制的小鼠中肥胖诱导的脂肪生成也增加。
这些数据表明,性腺功能减退症通过脂肪细胞肥大和脂肪生成损害葡萄糖代谢并增加肥胖诱导的脂肪量扩张。此外,我们的发现强调了睾酮、DHT 和雌二醇在调节总脂肪量和脂肪分布中的不同作用,并表明雄激素信号在体内阻止肥胖诱导的脂肪生成。